Pharmacologic studies of anticancer drugs with the human tumor stem cell assay

David S Alberts, Sydney E. Salmon, H. S. George Chen, Thomas E. Moon, Laurie Young, Earl A. Surwit

Research output: Contribution to journalArticle

71 Citations (Scopus)

Abstract

To optimize the human tumor stem cell assay (HTSCA) for clinical and research purposes we have carried out in vitro pharmacology studies. Useful observations were made in four areas. (1) Drug assay design: The predictive accuracy of the HTSCA depends on the in vitro testing of drug concentrations of less than 10% of those which are pharmacologically achievable with standard in vivo drug doses. The use of unrealistically high in vitro concentrations can accurately predict clinical drug resistance, but is likely to yield high false-positive rates of clinical response prediction. (2) Drug scheduling: For certain schedule-dependent drugs, as well as those with a prolonged plasma half-life and those used according to a repeated daily schedule, prolonged in vitro exposure (rather than 1 h) may be needed to provide an adequate in vitro design. For an accurate prediction of sensitivity of tumor colony-forming units (TCFUs) to continuous drug contact in the agar, concentrations should be in the range of 1/300 that used for the standard 1-h exposure prior to plating. (3) Drug combinations: In preliminary studies of combination chemotherapy in vitro we commonly observed at least additive effects with low doses of cis-platinum plus either vinblastine or adriamycin. (4) Drug bioactivation: Rat liver microsomes or S-9 fraction were used to activate cyclophosphamide for in vitro effect, and satisfactory dose-response curves were observed for the inhibition of TCFUs. Such pharmacologic studies will be required for a wide variety of standard and new agents and will probably become a regular aspect of investigation of new anticancer drugs.

Original languageEnglish (US)
Pages (from-to)253-264
Number of pages12
JournalCancer Chemotherapy and Pharmacology
Volume6
Issue number3
DOIs
StatePublished - 1981

Fingerprint

Tumor Stem Cell Assay
Stem cells
Tumors
Assays
Pharmaceutical Preparations
Appointments and Schedules
Stem Cells
Stem Cell Research
Vinblastine
Drug Design
Liver Microsomes
Drug Combinations
In Vitro Techniques
Combination Drug Therapy
Drug Resistance
Doxorubicin
Cyclophosphamide
Chemotherapy
Cisplatin
Agar

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pharmacology

Cite this

Pharmacologic studies of anticancer drugs with the human tumor stem cell assay. / Alberts, David S; Salmon, Sydney E.; George Chen, H. S.; Moon, Thomas E.; Young, Laurie; Surwit, Earl A.

In: Cancer Chemotherapy and Pharmacology, Vol. 6, No. 3, 1981, p. 253-264.

Research output: Contribution to journalArticle

Alberts, David S ; Salmon, Sydney E. ; George Chen, H. S. ; Moon, Thomas E. ; Young, Laurie ; Surwit, Earl A. / Pharmacologic studies of anticancer drugs with the human tumor stem cell assay. In: Cancer Chemotherapy and Pharmacology. 1981 ; Vol. 6, No. 3. pp. 253-264.
@article{88b0129bfec046b8bdebe81736474d42,
title = "Pharmacologic studies of anticancer drugs with the human tumor stem cell assay",
abstract = "To optimize the human tumor stem cell assay (HTSCA) for clinical and research purposes we have carried out in vitro pharmacology studies. Useful observations were made in four areas. (1) Drug assay design: The predictive accuracy of the HTSCA depends on the in vitro testing of drug concentrations of less than 10{\%} of those which are pharmacologically achievable with standard in vivo drug doses. The use of unrealistically high in vitro concentrations can accurately predict clinical drug resistance, but is likely to yield high false-positive rates of clinical response prediction. (2) Drug scheduling: For certain schedule-dependent drugs, as well as those with a prolonged plasma half-life and those used according to a repeated daily schedule, prolonged in vitro exposure (rather than 1 h) may be needed to provide an adequate in vitro design. For an accurate prediction of sensitivity of tumor colony-forming units (TCFUs) to continuous drug contact in the agar, concentrations should be in the range of 1/300 that used for the standard 1-h exposure prior to plating. (3) Drug combinations: In preliminary studies of combination chemotherapy in vitro we commonly observed at least additive effects with low doses of cis-platinum plus either vinblastine or adriamycin. (4) Drug bioactivation: Rat liver microsomes or S-9 fraction were used to activate cyclophosphamide for in vitro effect, and satisfactory dose-response curves were observed for the inhibition of TCFUs. Such pharmacologic studies will be required for a wide variety of standard and new agents and will probably become a regular aspect of investigation of new anticancer drugs.",
author = "Alberts, {David S} and Salmon, {Sydney E.} and {George Chen}, {H. S.} and Moon, {Thomas E.} and Laurie Young and Surwit, {Earl A.}",
year = "1981",
doi = "10.1007/BF00256978",
language = "English (US)",
volume = "6",
pages = "253--264",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - Pharmacologic studies of anticancer drugs with the human tumor stem cell assay

AU - Alberts, David S

AU - Salmon, Sydney E.

AU - George Chen, H. S.

AU - Moon, Thomas E.

AU - Young, Laurie

AU - Surwit, Earl A.

PY - 1981

Y1 - 1981

N2 - To optimize the human tumor stem cell assay (HTSCA) for clinical and research purposes we have carried out in vitro pharmacology studies. Useful observations were made in four areas. (1) Drug assay design: The predictive accuracy of the HTSCA depends on the in vitro testing of drug concentrations of less than 10% of those which are pharmacologically achievable with standard in vivo drug doses. The use of unrealistically high in vitro concentrations can accurately predict clinical drug resistance, but is likely to yield high false-positive rates of clinical response prediction. (2) Drug scheduling: For certain schedule-dependent drugs, as well as those with a prolonged plasma half-life and those used according to a repeated daily schedule, prolonged in vitro exposure (rather than 1 h) may be needed to provide an adequate in vitro design. For an accurate prediction of sensitivity of tumor colony-forming units (TCFUs) to continuous drug contact in the agar, concentrations should be in the range of 1/300 that used for the standard 1-h exposure prior to plating. (3) Drug combinations: In preliminary studies of combination chemotherapy in vitro we commonly observed at least additive effects with low doses of cis-platinum plus either vinblastine or adriamycin. (4) Drug bioactivation: Rat liver microsomes or S-9 fraction were used to activate cyclophosphamide for in vitro effect, and satisfactory dose-response curves were observed for the inhibition of TCFUs. Such pharmacologic studies will be required for a wide variety of standard and new agents and will probably become a regular aspect of investigation of new anticancer drugs.

AB - To optimize the human tumor stem cell assay (HTSCA) for clinical and research purposes we have carried out in vitro pharmacology studies. Useful observations were made in four areas. (1) Drug assay design: The predictive accuracy of the HTSCA depends on the in vitro testing of drug concentrations of less than 10% of those which are pharmacologically achievable with standard in vivo drug doses. The use of unrealistically high in vitro concentrations can accurately predict clinical drug resistance, but is likely to yield high false-positive rates of clinical response prediction. (2) Drug scheduling: For certain schedule-dependent drugs, as well as those with a prolonged plasma half-life and those used according to a repeated daily schedule, prolonged in vitro exposure (rather than 1 h) may be needed to provide an adequate in vitro design. For an accurate prediction of sensitivity of tumor colony-forming units (TCFUs) to continuous drug contact in the agar, concentrations should be in the range of 1/300 that used for the standard 1-h exposure prior to plating. (3) Drug combinations: In preliminary studies of combination chemotherapy in vitro we commonly observed at least additive effects with low doses of cis-platinum plus either vinblastine or adriamycin. (4) Drug bioactivation: Rat liver microsomes or S-9 fraction were used to activate cyclophosphamide for in vitro effect, and satisfactory dose-response curves were observed for the inhibition of TCFUs. Such pharmacologic studies will be required for a wide variety of standard and new agents and will probably become a regular aspect of investigation of new anticancer drugs.

UR - http://www.scopus.com/inward/record.url?scp=0019819229&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019819229&partnerID=8YFLogxK

U2 - 10.1007/BF00256978

DO - 10.1007/BF00256978

M3 - Article

C2 - 7318146

AN - SCOPUS:0019819229

VL - 6

SP - 253

EP - 264

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 3

ER -